ENT Updates
Clinical Research

Metformin And Dichloroacetate Combination Exert A Synergistic Effect On Cell Viability Of Oral Squamous Cell Carcinoma

1.

Dokuz Eylul University, 1Institute of Health Sciences

2.

School of Medicine, Department of Medical Biochemistry

3.

Izmir Univ. of Economics, Vocational School of Health Services, Dept. of Medical Laboratory Techniques, 35330 Balcova, Izmir-TURKEY

4.

Manisa Celal Bayar University, Faculty of Medicine, Department of Otolaryngology-Head and Neck Surgery, Manisa - TURKEY

5.

Institute of Oncology, Department of Translational Oncology, 35340 Inciralti, Izmir

ENT Updates 2019; 9: 68-73
DOI: 10.32448/entupdates.569464
Read: 982 Downloads: 699 Published: 28 January 2021

Objective: To assess the effects of Metformin, Dichloroacetate (DCA) and their combination on cell viability in oral squamous cell carcinoma, UPCI-SCC-131 cell line.

Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104 cells/well) and were treated with Metformin (1-16mM) and/or DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used to monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according to Chou-Talalay method.

Results: Half-maximal inhibitory concentrations (IC50) of Metformin and DCA were found to be 3mM and 23mM, respectively, for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells.

Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered as a candidate therapy for the “drug repositioning” of the treatment of oral cavity cancer.

Files
EISSN 2149-6498